BG102947A - Ionic conjugates with delayed release - Google Patents

Ionic conjugates with delayed release

Info

Publication number
BG102947A
BG102947A BG102947A BG10294798A BG102947A BG 102947 A BG102947 A BG 102947A BG 102947 A BG102947 A BG 102947A BG 10294798 A BG10294798 A BG 10294798A BG 102947 A BG102947 A BG 102947A
Authority
BG
Bulgaria
Prior art keywords
delayed release
ionic conjugates
relates
conjugates
ionic
Prior art date
Application number
BG102947A
Other languages
Bulgarian (bg)
English (en)
Inventor
Francis Ignatious
Thomas LOUGHMAN
Shalaby SHALABY
Franck Touraud
Original Assignee
Kinerton Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Limited filed Critical Kinerton Limited
Publication of BG102947A publication Critical patent/BG102947A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Lubricants (AREA)
BG102947A 1996-04-23 1998-11-23 Ionic conjugates with delayed release BG102947A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE960308A IE960308A1 (en) 1996-04-23 1996-04-23 Sustained release ionic conjugate
PCT/IE1997/000030 WO1997039738A2 (en) 1996-04-23 1997-04-22 Sustained release ionic conjugate

Publications (1)

Publication Number Publication Date
BG102947A true BG102947A (en) 1999-08-31

Family

ID=11041150

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102947A BG102947A (en) 1996-04-23 1998-11-23 Ionic conjugates with delayed release

Country Status (28)

Country Link
US (3) US6911218B2 (de)
EP (1) EP0904062B1 (de)
JP (2) JP3390177B2 (de)
KR (1) KR20000010621A (de)
CN (2) CN1186012C (de)
AT (1) ATE245970T1 (de)
BG (1) BG102947A (de)
BR (1) BR9708818A (de)
CA (1) CA2252826A1 (de)
CZ (2) CZ293965B6 (de)
DE (1) DE69723833T2 (de)
DK (1) DK0904062T3 (de)
EE (1) EE9800349A (de)
ES (1) ES2200172T3 (de)
HK (1) HK1018748A1 (de)
HU (1) HU224036B1 (de)
IE (1) IE960308A1 (de)
IL (1) IL126619A (de)
IS (1) IS4869A (de)
NO (1) NO984924L (de)
NZ (1) NZ332893A (de)
PL (2) PL188517B1 (de)
PT (1) PT904062E (de)
RU (1) RU2173137C2 (de)
SK (1) SK145598A3 (de)
TR (1) TR199802125T2 (de)
WO (1) WO1997039738A2 (de)
YU (1) YU46598A (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
EP1240896A3 (de) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Einkapseln von wasserlöslischen Peptiden
EP1204429B1 (de) * 1999-08-18 2003-10-29 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Formulierung zur verzögerten freisetzung von peptiden
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
EP1348444B1 (de) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US20040038948A1 (en) 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
KR100452752B1 (ko) * 2000-04-18 2004-10-12 주식회사 펩트론 단백질 함유 서방성 제제를 제조하는 방법 및 그 제제
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
MXPA03000821A (es) 2000-07-27 2004-03-18 Univ Rutgers Poliesteres y poliamidas terapeuticos.
CA2475187A1 (en) 2002-02-07 2003-08-14 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
EP1499367A1 (de) * 2002-04-24 2005-01-26 Poly-Med, Inc. Vielseitige beschichtung für endovaskuläre gefässstützen zur restenoseprophylaxe
AU2003289178A1 (en) * 2002-12-04 2004-06-23 Yasuo Hatate Agricultural-chemical microcapsule preparation made by oil/oil liquid drying and process for producing the same
EP2446894A3 (de) 2004-10-27 2013-02-20 University Of Denver Analoga des adrenocorticotropen Hormons und entsprechende Verfahren
EP1951260A4 (de) 2005-10-21 2009-11-11 Bezwada Biomedical Llc Funktionalisierte phenolische verbindungen und saugfähiger artikel daraus
US8007526B2 (en) 2005-12-01 2011-08-30 Bezwada Biomedical, Llc Difunctionalized aromatic compounds and polymers therefrom
WO2008034019A2 (en) 2006-09-13 2008-03-20 Polymerix Corporation Active agents and their oligomers and polymers
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
US8217134B2 (en) 2007-08-30 2012-07-10 Bezwada Biomedical, Llc Controlled release of biologically active compounds
US8048980B2 (en) 2007-09-17 2011-11-01 Bezwada Biomedical, Llc Hydrolysable linkers and cross-linkers for absorbable polymers
KR101224004B1 (ko) 2009-12-29 2013-01-22 주식회사 삼양바이오팜 단백질, 폴리펩타이드 또는 펩타이드 약물 전달용 고분자 및 그 제조방법, 및 단백질, 폴리펩타이드 또는 펩타이드 약물의 서방형 조성물 및 그 제조 방법
US9144579B2 (en) 2012-08-17 2015-09-29 Rutgers, The State University Of New Jersey Polyesters and methods of use thereof
US20140120057A1 (en) 2012-10-25 2014-05-01 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
US9862672B2 (en) 2013-05-29 2018-01-09 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
WO2015191742A1 (en) 2014-06-13 2015-12-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
US10543162B2 (en) 2015-04-10 2020-01-28 Rutgers, The State University Of New Jersey Kojic acid polymers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS5933214A (ja) 1982-08-19 1984-02-23 Mitsui Toatsu Chem Inc 微小球に製剤された制ガン剤の製造方法
DE3936191C2 (de) 1989-10-31 1996-10-17 Boehringer Ingelheim Kg Neue Copolymere aus Milchsäure und Weinsäure, ihre Herstellung sowie ihre Verwendung
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
DE4034334A1 (de) 1990-10-29 1992-04-30 Basf Ag Verwendung von weinsaeure einkondensiert enthaltenden polyestern als waschmittelzusatz, verfahren zur herstellung der polyester und polyester aus weinsaeure und tetracarbonsaeuren
ZA93929B (en) 1992-02-18 1993-09-10 Akzo Nv A process for the preparation of biologically active materialcontaining polymeric microcapsules.
CA2129514A1 (en) * 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
CA2144310A1 (en) 1992-09-22 1994-03-31 Richard G. Sinclair Degradation control of environmentally degradable disposable materials
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0678018B1 (de) * 1993-01-06 2003-04-09 Kinerton Limited Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
GB9310030D0 (en) 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
HUP0000732A3 (en) 1996-04-23 2000-11-28 Ipsen Mfg Ireland Ltd Acidic polylactic polymers
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate

Also Published As

Publication number Publication date
TR199802125T2 (xx) 1999-01-18
CN1626243A (zh) 2005-06-15
US20060121120A1 (en) 2006-06-08
JP3390177B2 (ja) 2003-03-24
PL188517B1 (pl) 2005-02-28
NZ332893A (en) 2000-03-27
JPH11508609A (ja) 1999-07-27
US20020041893A1 (en) 2002-04-11
EE9800349A (et) 1999-04-15
PL329606A1 (en) 1999-03-29
US7179490B2 (en) 2007-02-20
US7026431B2 (en) 2006-04-11
IS4869A (is) 1998-10-16
DE69723833T2 (de) 2004-05-13
SK145598A3 (en) 1999-03-12
ATE245970T1 (de) 2003-08-15
US20050074492A1 (en) 2005-04-07
RU2173137C2 (ru) 2001-09-10
HUP0000122A2 (hu) 2000-06-28
PL189319B1 (pl) 2005-07-29
CZ293965B6 (cs) 2004-08-18
AU721433B2 (en) 2000-07-06
AU2575197A (en) 1997-11-12
EP0904062A2 (de) 1999-03-31
NO984924D0 (no) 1998-10-22
IE960308A1 (en) 1997-11-05
CZ293822B6 (cs) 2004-08-18
WO1997039738A2 (en) 1997-10-30
IL126619A0 (en) 1999-08-17
HU224036B1 (hu) 2005-05-30
CN1186012C (zh) 2005-01-26
IL126619A (en) 2003-07-31
JP2003026606A (ja) 2003-01-29
CZ329998A3 (cs) 1999-02-17
PT904062E (pt) 2003-11-28
WO1997039738A3 (en) 1997-11-27
EP0904062B1 (de) 2003-07-30
BR9708818A (pt) 2000-01-04
YU46598A (sh) 1999-09-27
DE69723833D1 (de) 2003-09-04
NO984924L (no) 1998-12-21
US6911218B2 (en) 2005-06-28
HK1018748A1 (en) 2000-01-07
KR20000010621A (ko) 2000-02-25
CA2252826A1 (en) 1997-10-30
HUP0000122A3 (en) 2000-08-28
DK0904062T3 (da) 2003-10-20
ES2200172T3 (es) 2004-03-01
CN1216465A (zh) 1999-05-12

Similar Documents

Publication Publication Date Title
BG102947A (en) Ionic conjugates with delayed release
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
HUP9600903A2 (en) Copolymers based on oxy-alkylene-glycol-alkenyl-ether and unsaturated dicarboxylic acid derivative, process for producing thereof and the use thereof
GB2300982B (en) Low cost, high reliability soft start arrangement
AU4365496A (en) Continuous polymerization process for polyamides
ZA973901B (en) Alternative fuel.
AU1887897A (en) Devices for clamping wires, etc.
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
ZA961291B (en) Naphthyl compounds, intermediates, compositions, and methods.
AU3209097A (en) Neuroactive peptides
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
WO2000066650A3 (de) Carboxylfunktionelles additiv zur aufkondensierung von polyamiden
MX9602752A (es) Recubrimiento friccional para un disco de acoplamiento, asi como el disco de acoplamiento asi equipado.
CA2308386A1 (en) Method for digital signing of a message
ZA974270B (en) Pharmaceutical compositions based on diclofenac.
JO2017B1 (en) Pharmaceutical formula for infectious residence
ZA9811537B (en) Methods for regulating phagocytosis.
EP0921805A4 (de) Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen
AU1643697A (en) Improved equestrian stirrup iron
BG104801A (en) Indole-2,3-dione-3-oxime derivatives for therapeutical use
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
EP1764616A3 (de) Verfahren zur Identifizierung während der Apoptose modifizierter Proteine
AU1840497A (en) L-homoserine and l-homoserine lactone as bacteriostatic agents for m. tuberculosis and m. bovis
AU2268099A (en) Dendritic polymer-saccharide conjugate, pharmaceuticals containing said conjugate, method for its production and use thereof
WO2000063612A8 (en) Road lighting device